Oncopeptides

Recent Finacing

Series A

Recent Raise

Undisclosed

Oncopeptides AB is a Stockholm-based clinical-stage pharmaceutical developer, creating "cytosuperiors"—enhanced cytotoxic compounds; its lead candidate melflufen is an alkylating agent developed for Phase II multiple myeloma trials.